Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Over multiple experiments, LAKDC-reo generated significantly higher proportions of anti-Skov-3 CTL responses than neat reovirus, although the superiority of LAKDC-reo over iDC-reo did not reach statistical significance (Fig. 6 b ).

also in 111,027 other papers